Share on StockTwits

Equities researchers at Maxim Group decreased their target price on shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) from $29.00 to $23.00 in a research report issued on Wednesday. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 96.75% from the stock’s previous close.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) traded up 4.19% on Wednesday, hitting $12.18. 121,182 shares of the company’s stock traded hands. Tekmira Pharmaceuticals has a 52 week low of $4.61 and a 52 week high of $31.48. The stock has a 50-day moving average of $12.75 and a 200-day moving average of $14.57.

TKMR has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00. Separately, analysts at TheStreet downgraded shares of Tekmira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 11th. Finally, analysts at RBC Capital initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Friday, April 11th. They set an “outperform” rating and a $30.00 price target on the stock.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.